BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND NPM1, NPM, 4869, ENSG00000181163, P06748, B23, MGC104254 AND Prognosis
9 results:

  • 1. Nuclear PLD1 combined with npm1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma.
    Fu D; Yan J; Zhang Z; Liu Y; Ma X; Ding J; Yang S; Zhao R; Chang A; Gao C; Liu J; Zhao T; Wang X; Huang C; Gao S; Ma Y; Tang B; Feng Y; Wang H; Hao J
    Cancer Biol Med; 2023 Jun; 20(8):599-626. PubMed ID: 37381714
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Systematic analysis of the BET family in adrenocortical carcinoma: The expression, prognosis, gene regulation network, and regulation targets.
    Situ Y; Liang Q; Zeng Z; Chen J; Shao Z; Xu Q; Lu X; Cui Y; Zhang J; Lu L; Deng L
    Front Endocrinol (Lausanne); 2023; 14():1089531. PubMed ID: 36793283
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Immortalization-upregulated protein promotes pancreatic cancer progression by regulating npm1/FHL1-mediated cell-cycle-checkpoint protein activity.
    Luo Q; Pan Y; Fu Q; Zhang X; Zhou S; Yu P; Tian H; Liu P; Chen S; Zhang H; Qin T
    Cell Biol Toxicol; 2023 Oct; 39(5):2069-2087. PubMed ID: 35142956
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Single-cell transcriptomics reveals heterogeneous progression and EGFR activation in pancreatic adenosquamous carcinoma.
    Zhao X; Li H; Lyu S; Zhai J; Ji Z; Zhang Z; Zhang X; Liu Z; Wang H; Xu J; Fan H; Kou J; Li L; Lang R; He Q
    Int J Biol Sci; 2021; 17(10):2590-2605. PubMed ID: 34326696
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. PRMT1 promotes the tumor suppressor function of p14
    Repenning A; Happel D; Bouchard C; Meixner M; Verel-Yilmaz Y; Raifer H; Holembowski L; Krause E; Kremmer E; Feederle R; Keber CU; Lohoff M; Slater EP; Bartsch DK; Bauer UM
    EMBO J; 2021 Jul; 40(13):e106777. PubMed ID: 33999432
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Expression of CD24 in plasma, exosome and ovarian tissue samples of serous ovarian cancer patients.
    Soltész B; Lukács J; Szilágyi E; Márton É; Szilágyi Bónizs M; Penyige A; Póka R; Nagy B
    J Biotechnol; 2019 Jun; 298():16-20. PubMed ID: 30959137
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. The expression profile and prognostic value of APE/Ref-1 and npm1 in high-grade serous ovarian adenocarcinoma.
    Fan X; Wen L; Li Y; Lou L; Liu W; Zhang J
    APMIS; 2017 Oct; 125(10):857-862. PubMed ID: 28766835
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. npm1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells.
    Zhu Y; Shi M; Chen H; Gu J; Zhang J; Shen B; Deng X; Xie J; Zhan X; Peng C
    Oncotarget; 2015 Aug; 6(25):21443-51. PubMed ID: 26068981
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. [Importance of proliferative potential (as the ratio of a proliferative cells number and duration of mitosis) in diagnoses of malignant degree and prognosis of adrenocortical cancer].
    Raĭkhlin NT; Bukaeva IA; Filimoniuk AV; Smirnova EA; Probatova NA; Pavlovskaia AI; Shabanov MA; Ponomareva MV
    Arkh Patol; 2011; 73(5):43-7. PubMed ID: 22288173
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.